The STAMPEDE trial is one of the most quoted by scholars that study the efficacy and safety of metabolic surgery in comparison to intensive medical therapy to achieve glycaemic control, T2D remission and other benefits for patients that have this diagnosis.
In his talk in the XXI Brazilian Bariatric Surgery Congress, organized by the Brazilian Society of Bariatric and Metabolic Surgery (SBCBM), Dr. Philip Schauer explained how it was built and the overall outcomes for patients not only physical, but also mental health and quality of life.
From a pool of 150 patients and 90% retention over 5 years, the results of the study formed what could be considered a baseline to support the beneficial response of the surgical intervention to the diabetic patients and the illness’ consequences, like the decrease of cardiometabolic risk factors, reduction on dosage or elimination of the use of insulin or other pharmaceuticals and most important, a significant gain in quality of life reported by the patients.
Dr. Schauer recognizes this trial’s beneficial legacy, - even considering its single center aspect, what can be considered an impediment to generalize the result effectively - but says that the next step is taking it to the next level with a Multicenter RCT for metabolic surgery and solidify the benefits of it as a golden parameter to the next phase of metabolic surgery.
This aligns with this year's SBCBM Congress main theme and discussions of the new treatments to bring back quality of life for people suffering from overweight and associated diseases.